Tirzepatide vs Retatrutide: Dual vs Triple Incretin Agonists
Comparing the dual GIP/GLP-1 agonist with the next-generation triple GIP/GLP-1/Glucagon agonist.
Tirzepatide
GIP / GLP-1 Dual Agonist
A 39-amino acid synthetic peptide that simultaneously activates GIP and GLP-1 receptors. Demonstrated greater weight loss than any approved single-agonist in clinical trials.
Retatrutide
GLP-1 / GIP / Glucagon Triple Agonist
A novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — the first of its kind in human Phase 2 trials. Early data suggests it may surpass dual agonists.
Executive Research Summary
While Tirzepatide revolutionized metabolic medicine as a dual GIP/GLP-1 agonist, Retatrutide introduces a third target: the Glucagon receptor. By combining GLP-1 (satiety), GIP (metabolism & insulin sensitivity), and Glucagon (energy expenditure & hepatic fat clearance), Retatrutide achieved an unprecedented 24.2% mean weight reduction in Phase 2 clinical trials at 48 weeks.
Key Differentiating Factors
Receptor Agonism: Tirzepatide is a dual agonist (GIP/GLP-1); Retatrutide is a triple agonist (GLP-1/GIP/Glucagon).
Energy Expenditure: Retatrutide actively increases resting thermogenesis and metabolic rate via hepatic glucagon receptor activation.
Speed of Weight Loss: Retatrutide achieved 24.2% mean weight loss at 48 weeks, outpacing Tirzepatide's 20.9%–22.5% at 72 weeks.
Liver Fat Clearance: Retatrutide cleared over 80% of hepatic steatosis (fatty liver) in trial sub-cohorts, with up to 86% of patients resolving NAFLD/MASLD.
Head-to-Head Specification Matrix
| Comparison Metric | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor Targets | GIP + GLP-1 (Dual) | GIP + GLP-1 + Glucagon (Triple) Advantage |
| Weight Loss at 48 Weeks | ~17% – 19% | ~24.2% (highest dose) Advantage |
| Regulatory Status | FDA Approved (Mounjaro / Zepbound) Advantage | Phase 3 Clinical Trials (Investigational) |
| Heart Rate & Hemodynamics | Modest transient heart rate increase (1-3 bpm) Advantage | Dose-dependent heart rate increase (peak at ~24 weeks, ~4-9 bpm) |
Head-to-Head Research Verdict
Choose Tirzepatide If:
Commercial research protocols requiring an approved, standardized reference standard with full safety verification.
Choose Retatrutide If:
Cutting-edge metabolic research investigating non-alcoholic fatty liver disease (MASLD), resting thermogenesis, and severe obesity resistance.
Bottom Line: Retatrutide is the most potent metabolic compound developed to date in human trials, while Tirzepatide represents the current clinical gold standard.